Evolutionary survival of a species is largely a function of its reproductive fitness. In mammals, a sparsely populated and widely dispersed network of hypothalamic neurons, the gonadotropin-releasing hormone (GnRH) neurons, serve as the pilot light of reproduction via coordinated secretion of GnRH. Since it first description, human GnRH deficiency has been recognized both clinically and genetically as a heterogeneous disease. A spectrum of different reproductive phenotypes comprised of congenital GnRH deficiency with anosmia (Kallmann syndrome), congenital GnRH deficiency with normal olfaction (normosmic idiopathic hypogonadotropic hypogonadism), and adult-onset hypogonadotropic hypogonadism has been described. In the last two decades, several genes and pathways which govern GnRH ontogeny have been discovered by studying humans with GnRH deficiency. More importantly, detailed study of these patients has highlighted the emerging theme of oligogenicity and genotypic synergism, and also expanded the phenotypic diversity with the documentation of reversal of GnRH deficiency later in adulthood in some patients. The underlying genetic defect has also helped understand the associated nonreproductive phenotypes seen in some of these patients. These insights now provide practicing clinicians with targeted genetic diagnostic strategies and also impact on clinical management.

Keywords:
Gonadotropin-releasing hormone deficiency, Gonadotropin-releasing hormone neuronal ontogeny, Puberty, Kallmann syndrome, Hypogonadotropic hypogonadism
1.
Wray S, Hoffman G: A developmental study of the quantitative distribution of LHRH neurons within the central nervous system of postnatal male and female rats. J Comp Neurol 1986;252:522–531.
2.
Merchenthaler I, et al: Gonadotropin-releasing hormone (GnRH) neurons and pathways in the rat brain. Cell Tissue Res 1984;237:15–29.
3.
Grumbach MM: A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. J Clin Endocrinol Metab 2005;90:3122–3127.
4.
Conn PM, Crowley WF Jr: Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391–405.
5.
Antunes JL, et al: Luteinizing hormone-releasing hormone in human pituitary blood. J Neurosurg 1978;49:382–386.
6.
Terasawa E: Luteinizing hormone-releasing hormone (LHRH) neurons: mechanism of pulsatile LHRH release. Vitam Horm 2001;63:91–129.
7.
Lehman MN, et al: Immunocytochemical localization of luteinizing hormone-releasing hormone (LHRH) pathways in the sheep brain during anestrus and the mid-luteal phase of the estrous cycle. J Comp Neurol 1986;244:19–35.
8.
Schwanzel-Fukuda M, Pfaff DW: Origin of luteinizing hormone-releasing hormone neurons. Nature 1989;338:161–164.
9.
Wray S, Grant P, Gainer H: Evidence that cells expressing luteinizing hormone-releasing hormone mRNA in the mouse are derived from progenitor cells in the olfactory placode. Proc Natl Acad Sci USA 1989;86:8132–8136.
10.
Wray S, Nieburgs A, Elkabes S: Spatiotemporal cell expression of luteinizing hormone-releasing hormone in the prenatal mouse: evidence for an embryonic origin in the olfactory placode. Brain Res Dev Brain Res 1989;46:309–318.
11.
Fueshko S, Wray S: LHRH cells migrate on peripherin fibers in embryonic olfactory explant cultures: an in vitro model for neurophilic neuronal migration. Dev Biol 1994;166:331–348.
12.
Schwanzel-Fukuda M: Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Microsc Res Tech 1999,44:2–10.
13.
Belchetz PE, et al: Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978;202:631–633.
14.
Gibson MJ, et al: Mating and pregnancy can occur in genetically hypogonadal mice with preoptic area brain grafts. Science 1984;225:949–951.
15.
Gibson MJ, Miller GM, Silverman AJ: Pulsatile luteinizing hormone secretion in normal female mice and in hypogonadal female mice with preoptic area implants. Endocrinology 1991;128:965–971.
16.
Cariboni A, et al: The product of X-linked Kallmann’s syndrome gene (KAL1) affects the migratory activity of gonadotropin-releasing hormone (GnRH)-producing neurons. Hum Mol Genet 2004;13:2781–2791.
17.
Maestre de San Juan A: Teratologia: falta total de los nervios olfactorios con anosmia en un individuo en quien existia una atrofia congénita de los testículos y miembro viril. Siglo Medico 1856,3:211–221.
18.
Kallmann F, Schoenfeld W, Barrera S: The genetic aspects of primary eunuchoidism. Am J Ment Defic 1944;48:203–236.
19.
de Morsier G: Etudes sur les dysraphies cranio-encephaliques. Schweiz Arch Neurol Psychiatr 1954;74:309–361.
20.
Schally AV, et al: Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971;43:393–399.
21.
Amoss M, et al: Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of ovine origin. Biochem Biophys Res Commun 1971;44:205–210.
22.
Naftolin F, Harris GW, Bobrow M: Effect of purified luteinizing hormone releasing factor on normal and hypogonadotrophic anosmic men. Nature 1971;232:496–497.
23.
Hoffman AR, Crowley WF Jr: Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982;307:1237–1241.
24.
de Roux N, et al: Loss of function mutations of the GnRH receptor: a new cause of hypogonadotropic hypogonadism. J Pediatr Endocrinol Metab 1999;12(suppl 1):267–275.
25.
Waldstreicher J, et al: The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J Clin Endocrinol Metab 1996;81:4388–4395.
26.
Pitteloud N, et al: Reversible Kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the fibroblast growth factor receptor 1 gene. J Clin Endocrinol Metab 2005;90:1317–1322.
27.
Pitteloud N, et al: Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol 2006;254–255:60–69.
28.
Nachtigall LB, et al: Adult-onset idiopathic hypogonadotropic hypogonadism – a treatable form of male infertility. N Engl J Med 1997;336:410–415.
29.
Pitteloud N, et al: Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 2007;117:457–463.
30.
Dodé C, Hardelin JP: Kallmann syndrome. Eur J Hum Genet 2009;17:139–146.
31.
Raivio T, et al: Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007;357:863–873.
32.
Ballabio A, et al: X-linked ichthyosis, due to steroid sulphatase deficiency, associated with Kallmann syndrome (hypogonadotropic hypogonadism and anosmia): linkage relationships with Xg and cloned DNA sequences from the distal short arm of the X chromosome. Hum Genet 1986;72:237–240.
33.
Bick D, et al: Male infant with ichthyosis, Kallmann syndrome, chondrodysplasia punctata, and an Xp chromosome deletion. Am J Med Genet 1989;33:100–107.
34.
Schwanzel-Fukuda M, Bick D, Pfaff DW: Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Brain Res Mol Brain Res 1989;6:311–326.
35.
Franco B, et al: A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991;353:529–536.
36.
Legouis R, et al: The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991;67:423–435.
37.
Hardelin JP: Kallmann syndrome: towards molecular pathogenesis. Mol Cell Endocrinol 2001;179:75–81.
38.
Hu Y, et al: Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann’s syndrome, with heparan sulphate and urokinase-type plasminogen activator. Biochem J 2004;384:495–505.
39.
Bulow HE, et al: Heparan sulfate proteoglycan-dependent induction of axon branching and axon misrouting by the Kallmann syndrome gene kal-1. Proc Natl Acad Sci USA 2002;99:6346–6351.
40.
Hardelin JP, et al: Anosmin-1 is a regionally restricted component of basement membranes and interstitial matrices during organogenesis: implications for the developmental anomalies of X chromosome-linked Kallmann syndrome. Dev Dyn 1999;215:26–44.
41.
Cadman SM, et al: Molecular pathogenesis of Kallmann’s syndrome. Horm Res 2007;67:231–242.
42.
Kim SH, et al: Diversity in fibroblast growth factor receptor 1 regulation: learning from the investigation of Kallmann syndrome. J Neuroendocrinol 2008;20:141–163.
43.
Oliveira LM, et al: The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab 2001;86:1532–1538.
44.
Quinton R, et al: Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. Clin Endocrinol (Oxf) 2001;55:163–174.
45.
Hardelin JP, Dodé C: The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. Sex Dev 2008;2:181–193.
46.
Tsai PS, Gill JC: Mechanisms of disease: insights into X-linked and autosomal-dominant Kallmann syndrome. Nat Clin Pract Endocrinol Metab 2006;2:160–171.
47.
Andrenacci D, et al: Functional dissection of the Drosophila Kallmann’s syndrome protein DmKal-1. BMC Genet 2006;7:47.
48.
Hardelin JP, et al: Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. Hum Mol Genet 1993;2:373–377.
49.
de Roux N, et al: Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003;100:10972–10976.
50.
Seminara SB, et al: The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349:1614–1627.
51.
Muir AI, et al: AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem 2001;276:28969–28975.
52.
Colledge WH: Kisspeptins and GnRH neuronal signalling. Trends Endocrinol Metab 2009;20:115–121.
53.
Ohtaki T, et al: Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001;411:613–617.
54.
Chan YM, Broder-Fingert S, Seminara SB: Reproductive functions of kisspeptin and Gpr54 across the life cycle of mice and men. Peptides 2009;30:42–48.
55.
Tenenbaum-Rakover Y, et al: Neuroendocrine phenotype analysis in five patients with isolated hypogonadotropic hypogonadism due to a L102P inactivating mutation of GPR54. J Clin Endocrinol Metab 2007;92:1137–1144.
56.
Semple RK, et al: Two novel missense mutations in g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005;90:1849–1855.
57.
Pallais JC, et al: Neuroendocrine, gonadal, placental, and obstetric phenotypes in patients with IHH and mutations in the G-protein coupled receptor, GPR54. Mol Cell Endocrinol 2006;254–255:70–77.
58.
Castellano JM, et al: KiSS-1/kisspeptins and the metabolic control of reproduction: physiologic roles and putative physiopathological implications. Peptides 2009;30:139–145.
59.
Hauge-Evans AC, et al: A role for kisspeptin in islet function. Diabetologia 2006;49:2131–2135.
60.
Robertson JL, et al: Circadian regulation of Kiss1 neurons: implications for timing the preovulatory gonadotropin-releasing hormone/luteinizing hormone surge. Endocrinology 2009;150:3664–3671.
61.
Teles MG, et al: A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 2008;358:709–715.
62.
Plant TM, Ramaswamy S: Kisspeptin and the regulation of the hypothalamic-pituitary-gonadal axis in the rhesus monkey (Macaca mulatta). Peptides 2009;30:67–75.
63.
Beenken A, Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235–253.
64.
Dodé C, et al: Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003;33:463–465.
65.
Mohammadi M, Olsen SK, Ibrahimi OA: Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107–137.
66.
Yeh BK, et al: Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci USA 2003;100:2266–2271.
67.
Pitteloud N, et al: Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2006;103:6281–6286.
68.
Trarbach EB, et al: Novel fibroblast growth factor receptor 1 mutations in patients with congenital hypogonadotropic hypogonadism with and without anosmia. J Clin Endocrinol Metab 2006;91:4006–4012.
69.
Zhang X, et al: Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. J Biol Chem 2006;281:15694–15700.
70.
Meyers EN, Lewandoski M, Martin GR: An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat Genet 1998;18:136–141.
71.
Falardeau J, et al: Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008;118:2822–2831.
72.
Gonzalez-Martinez D, et al: Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism. J Neurosci 2004;24:10384–10392.
73.
Dodé C, Hardelin JP: Kallmann syndrome: fibroblast growth factor signaling insufficiency? J Mol Med 2004;82:725–734.
74.
Gibson MJ, Ingraham L, Dobrjansky A: Soluble factors guide gonadotropin-releasing hormone axonal targeting to the median eminence. Endocrinology 2000;141:3065–3071.
75.
Hebert JM, et al: FGF signaling through FGFR1 is required for olfactory bulb morphogenesis. Development 2003;130:1101–1111.
76.
Tsai PS, et al: Targeted expression of a dominant-negative fibroblast growth factor (FGF) receptor in gonadotropin-releasing hormone (GnRH) neurons reduces FGF responsiveness and the size of GnRH neuronal population. Mol Endocrinol 2005;19:225–236.
77.
Storm EE, Rubenstein JL, Martin GR: Dosage of Fgf8 determines whether cell survival is positively or negatively regulated in the developing forebrain. Proc Natl Acad Sci USA 2003;100:1757–1762.
78.
Li M, et al: Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle. Mol Pharmacol 2001;59:692–698.
79.
Ng KL, et al: Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. Science 2005;308:1923–1927.
80.
Matsumoto S, et al: Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. Proc Natl Acad Sci USA 2006;103:4140–4145.
81.
Pitteloud N, et al: Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2007;104:17447–17452.
82.
Bullock CM, Li JD, Zhou QY: Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists. Mol Pharmacol 2004;65:582–588.
83.
Schweitz H, et al: MIT(1), a black mamba toxin with a new and highly potent activity on intestinal contraction. FEBS Lett 1999;461:183–188.
84.
LeCouter J, Lin R, Ferrara N: The role of EG-VEGF in the regulation of angiogenesis in endocrine glands. Cold Spring Harb Symp Quant Biol 2002;67:217–221.
85.
LeCouter J, et al: Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci USA 2004;101:16813–16818.
86.
Negri L, et al: Nociceptive sensitization by the secretory protein Bv8. Br J Pharmacol 2002;137:1147–1154.
87.
Hu WP, et al: Altered circadian and homeostatic sleep regulation in prokineticin 2-deficient mice. Sleep 2007;30:247–256.
88.
Cheng MY, et al: Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 2002;417:405–410.
89.
Prosser HM, et al: Prokineticin receptor 2 (Prokr2) is essential for the regulation of circadian behavior by the suprachiasmatic nuclei. Proc Natl Acad Sci USA 2007;104:648–653.
90.
Cole LW, et al: Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab 2008;93:3551–3559.
91.
Dodé C, et al: Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006;2:e175.
92.
Cheng CK, Leung PC: Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005;26:283–306.
93.
Chan YM, et al: GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2009;106:11703–11708.
94.
Bouligand J, et al: Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med 2009;360:2742–2748.
95.
Tsutsumi M, et al: Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. Mol Endocrinol 1992;6:1163–1169.
96.
Stojilkovic SS, Reinhart J, Catt KJ: Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 1994;15:462–499.
97.
Millar RP, et al: Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25:235–275.
98.
Karten MJ, Rivier JE: Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 1986;7:44–66.
99.
de Roux N, et al: A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997;337:1597–1602.
100.
Karges B, Karges W, de Roux N: Clinical and molecular genetics of the human GnRH receptor. Hum Reprod Update 2003;9:523–530.
101.
Leanos-Miranda A, Janovick JA, Conn PM: Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002;87:4825–4828.
102.
Beranova M, et al: Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2001;86:1580–1588.
103.
Pitteloud N, et al: The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 2001;86:2470–2475.
104.
Topaloglu AK, et al: TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat Genet 2009;41:354–358.
105.
Pennefather JN, et al: Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445–1463.
106.
Mileusnic D, et al: Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study. Neuroscience 1999;89:1269–1290.
107.
Satake H, Kawada T: Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors. Curr Drug Targets 2006;7:963–974.
108.
Rance NE, Bruce TR: Neurokinin B gene expression is increased in the arcuate nucleus of ovariectomized rats. Neuroendocrinology 1994;60:337–345.
109.
Rance NE: Menopause and the human hypothalamus: evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. Peptides 2009;30:111–122.
110.
Siuciak JA, et al: Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits. Psychopharmacology (Berl) 2007;194:185–195.
111.
Gianetti E, et al: TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab 2010; 95:2857–2867.
112.
Wakabayashi Y, et al: Neurokinin B and dynorphin A in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile gonadotropin-releasing hormone secretion in the goat. J Neurosci 2010;30:3124–3132.
113.
Navarro VM, et al: Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the mouse. J Neurosci 2009;29:11859–11866.
114.
Kramer PR, Wray S: Novel gene expressed in nasal region influences outgrowth of olfactory axons and migration of luteinizing hormone-releasing hormone (LHRH) neurons. Genes Dev 2000;14:1824–1834.
115.
Miura K, Acierno JS Jr, Seminara SB: Characterization of the human nasal embryonic LHRH factor gene, NELF, and a mutation screening among 65 patients with idiopathic hypogonadotropic hypogonadism (IHH). J Hum Genet 2004;49:265–268.
116.
Yu RN, et al: The role of DAX-1 in reproduction. Trends Endocrinol Metab 1998;9:169–175.
117.
Farooqi S, O’Rahilly S: Genetics of obesity in humans. Endocr Rev 2006;27:710–718.
118.
Vissers LE, et al: Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 2004;36:955–957.
119.
Pinto G, et al: CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development. J Clin Endocrinol Metab 2005;90:5621–5626.
120.
Kim HG, et al: Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2008;83:511–519.
121.
Jongmans MC, et al: CHD7 mutations in patients initially diagnosed with Kallmann syndrome – the clinical overlap with CHARGE syndrome. Clin Genet 2009;75:65–71.
122.
Pennisi E: What determines species diversity? Science 2005;309:90.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.